VENETOCLAX
venetoclax 100 mg tablet, 120
VENETOCLAX (15358H)
15358H
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Second and final continuing treatment (treatment cycles 9 to 14 inclusive) of first-line
therapy with acalabrutinib
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 120 | # of repeats: 5 | DPMQ: $7,404.80 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Venclexta | |||||